FARMAKOTERAPI DAN REHABILITASI PSIKOSOSIAL PADA SKIZOFRENIA

AULIANI HAFIFAH, IRMA PUSPITASARI, RANO SINURAYA

Abstract


Skizofrenia termasuk ke dalam gangguan multiple psychiatric dengan komorbiditas dan mortalitas yang terus meningkat. Pengobatan skizofrenia telah banyak berkembang dan mengalami kemajuan. Fokus terapinya telah berubah, dari hanya menangani gejala psikosis hingga mengendalikan fungsi kerja dan sosial. Review artikel ini memberi gambaran mengenai farmakoterapi dan rehabilitasi sosial yang tengah berkembang. Review dilakukan terhadap 16 jurnal, 4 handbook dan 1 situs terpercaya, yaitu WHO yang membahas terapi skizofrenia. Berdasarkan studi yang dilakukan, farmakoterapi skizofrenia yang paling sering digunakan adalah antipsikotik. Klozapin tidak dijadikan sebagai lini pertama, tetapi digunakan pada kasus TRS (Treatment-Resistance Schizophrenia). Rehabilitasi psikososial, baik terapi kognitif maupun SST berperan sebagai komponen kunci dalam proses pemulihan dan berguna untuk menilai stabilitas gejala serta fungsi kerja-sosial pada penderita skizofrenia.

Kata kunci: skizofrenia, farmakoterapi, psikososial, antipsikotik, terapi kognitif, SST.

References


DAFTAR PUSTAKA

American Psychiatric Association. 2013. Diagnostic and statistical manual of mental disorders, fifth edition (DSM-V). Washington (DC): American Psychiatric Publishing.

Barch DM. 2010. Pharmacological strategies for enhancing cognition in schizophrenia. Curr Top Behav Neurosci, 4 p: 43--96.

Biedermann F, Fleischhacker WW. 2011. Emerging drugs for schizophrenia. Expert Opin Emerg Drugs, 16 p: 271--282.

Bruijnzeel, D., Uma, S., Rajiv, T. 2014. Antipsychotic treatment of schizophrenia: An Update. Asian Journal of Psychiatry, 635 p: 1-5

Chisholm-Burns, M. A. et al., 2016. Pharmacotherapy Principles & Practice Fourth Edition. New York: McGraw-Hill Education.

Conn PJ, Tamminga C, Schoepp DD, Lindsley C. 2008. Schizophrenia: moving beyond monoamine antagonists. Mol Interv, 8 p: 99-107.

Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS et al. 2009. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry, 166: 675--682.

Dipiro, et al. 2011. Pharmacotherapi: A pathophysiologic approach 8th Edition. New York. McGraw-Hill

Ferrin M, Helen G, Arianna M, Joseph MR. 2016. Using antipsychotic medication for the treatment of schizophrenia in children and adolescents. Geneva: International Association for Child and Adolescents Psychiatry and Allied Proffesions (IACA PAP) Textbook of Child and Adolescent Mental Health

Fleischhacker WW. 1995. New drugs for the treatment of schizophrenic patients. Acta Psychiatr Scand (Suppl), 388 p: 24--30.

Foster et al., 2017. Combination Antipsychotic Therapies An Analysis From a Longitudinal Pragmatic Trial. Journal of Clinical Psychopharmacology, 37(5) p:595-599

Goldstein JI, Jarskog LF, Hilliard C, Alfirevic A, Duncan L, Fourches D, et al. 2014. Clozapine-induced agranulocytosis is associated with rare HLA-DQBI and HLA-B alleles. Nat Commun, 5 p: 4757.

Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting. 2008. Nice. Eur Neuropsychopharmacol. 2009; 19(7):520–32.

Guyton dan Hall. 2011. Guyron and Hall Medical Physiology 12th Edition. Philadephia: Elesevier

Hanson, E., Kristin, H., Daniel, W. 2010. Assesment of Pharmacotherapy for Negative Symptoms of Schizophrenia. Curr Psychiatry, 12 p: 563-571

Hanson, E., Kristin, H., Daniel, W. 2010. Assesment of Pharmacotherapy of Negative Symptoms of Schizophrenia. Curr Psychiatry Rep. 12, p: 563-571

Haukka J, Tiihonen J, Harkanen T, Lonnqvist J. 2008. Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. Pharmacoepidemiology and Drug Safety 17, p: 686–696.

Heckers, S., Tandon, R., Bustillo, J. 2010. Catatonia in the DSM – shall we move or not? Schizophr. Bull. 36, p: 205–207.

Hill SK, Bishop JR, Palumbo D, Sweeney JA. 2010. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev Neurother, 10 p: 43--57.

Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R et al. 2010. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther, 334 p: 171-181.

Ivan Os, J., Kapur, S., 2009. Schizophrenia. Lancet 374, p: 635–645.

Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371: 1085--1097.

Kane J, Honigfeld G, Singer J, Meltzer H. 1988. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry, 45 p: 789--796.

Kane JM. 1989. The current status of neuroleptic therapy. J Clin Psychiatry, 50 p: 322--328.

Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM et al. 2007. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry, 64 p: 633--647.

Kern et al. 2009. Psychosocial Treatments to Promote Functional Recovery in Schizophrenia. Schizophrenia Bulletin, 35(2) p: 347-361

Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. 2009. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet, 373 p: 31-41.

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 353 p: 1209--1223.

Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS et al. 2005. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry, 62 p: 361--370.

Maher KN, Tan M, Tossell JW, Weisinger B, Gochman P, Miller R, et al. Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia. 2013. J Child Adolesc Psychopharmacol, 23(2) p: 110–6.

Marder SR, Van Putten T, Schatzberg AF, Nemeroff CB. 1995. Antipsychotic medications. The American Psychiatric Press Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press p: 247--261.

Meltzer, H.Y. 2015. Pharmacotherapy of cognition in schizophrenia. Current opinion in behavioral therapy, 4 p: 115-121

Miyake N, Miyamoto S, Jarskog LF. 2012. New serotonin/dopamine antagonists for the treatment of schizophrenia: are we making real progress? Clin Schizophr Relat Psychoses in press.

Miyamoto S, Duncan GE, Marx CE, Lieberman JA. 2005. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry, 10 p: 79-104.

Miyamoto S, Merrill DB, Lieberman JA, Fleischhacker WW, Marder SR. 2008. Antipsychotic drugs. In: Tasman A, Kay J, Lieberman JA, et al. (eds). Psychiatry, 3rd edn. Chichester: John Wiley & Sons, p: 2161--2201.

Miyamoto S., Miyake N., Jarskog LF., Fleischckhhacker WW and Lieberman. 2012. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Molecular Psychiatry, 17 p: 1206-1227

Morrison, et al. 2014. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single blind randomised controlled trial. Lancet, 383 p: 1395-403

Nasrallah HA, Targum SD, Tandon R, McCombs JS, Ross R. 2014. Defining and measuring clinical effectiveness in the treatment of schizophrenia. Psychiatr Serv, 56(3) p: 273-282

National Institute for Clinical Excellence. Psychosis and schizophrenia in children and young people: Recognition and management. UK: NICE, 2013.

Osser DN, Roudsari MJ, Manschreck T. 2013. The psychopharmacology algorithm project at the Harvard South Shore Program: An update on schizophrenia. Harvard Review of Psychiatry, 21: 18–40. [PubMed: 23656760]

Sadock, Benjamin J, dan Virginia A. Sadock. 2010. Buku Ajar Psikiatri Klinis. Jakarta: EGC

Tandon, R., Carpenter, W.T. 2012. DSM-5 status of psychotic disorders. Schizophr. Bull. 38, p: 369–370.

Tandon, R., Keshavan, M.S., Nasrallah, A. 2008. Schizophrenia, ‘‘Just the Facts’’. What we know in 2008. Part 1: Overview. Schizophr. Res, 100 p: 4–19.

Tandon, R., Nasrallah, H.A., Keshavan, M.S. 2009. Schizophrenia, ‘‘Just the facts’’ 4. Clinical features and conceptualization. Schizophr. Res, 110 p: 1–23.

Thompson A, Lavedan C, Volpi S. 2010. Absence of weight gain association with the HTRC-759C/T polymorphism in patients with schizophrenia treated with iloperidone. Psychiatr Res, 165 p:271–273.

Tilhonen et al., 2017. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia. JAMA Psychiatry, 74(2) p: 686-693.

Weber J, McCormack PL. 2009. Asenapine. CNS Drugs, 23 p:781–792.

Weinbrenner, S., Assion H-J., Stargardt T., et al. 2009. Drug Prescription Pattern in Schizophrenia Outpatients: Analysis of Data from a German Health Insurance Fund. Pharmacopsychiatry, 42 p: 66 – 71

Wells, et al. 2009. Pharmacotherapy Handbook 7th Edition. New York: McGraw-Hill

Wells, et al. 2015. Pharmacotherapy Handbook 9th Edition. New York: McGraw-Hill

WHO. 2011. http://www.who.int/mental_health/management/schizophrenia/en/ [diakses 20 Juni 2018).




DOI: https://doi.org/10.24198/jf.v16i2.17525

DOI (PDF (Bahasa Indonesia)): https://doi.org/10.24198/jf.v16i2.17525.g8757

Article metrics

Abstract views : 0 | views : 0

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 AULIANI HAFIFAH, IRMA PUSPITASARI, RANO SINURAYA